Gilead (Kite) and 2seventy Bio Present Study Designs for their Next-Generation Assets Targeting Hematologic Malignancies; ASCO 2022 Analysis 3
Here is a brief preview of this blast: ASCO 2022 Analysis 3: Gilead (Kite) and 2seventy bio reported study designs for their novel assets treating B cell malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: